Eupraxia Pharmaceuticals Inc. (EPRX.TO)
CAD 4.58
(3.15%)
CAD 4.58
(3.15%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 25.54 Million CAD | 76.03% |
| 2022 | 14.51 Million CAD | 24.36% |
| 2021 | 11.66 Million CAD | -49.52% |
| 2020 | 23.11 Million CAD | 7.94% |
| 2019 | 21.41 Million CAD | 49.3% |
| 2018 | 14.34 Million CAD | 1849.47% |
| 2017 | 735.81 Thousand CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 25.07 Million CAD | 29.43% |
| 2024 Q2 | 15.92 Million CAD | -36.49% |
| 2023 Q4 | 19.37 Million CAD | 0.44% |
| 2023 Q1 | 12.81 Million CAD | -11.67% |
| 2023 Q3 | 19.28 Million CAD | 31.58% |
| 2023 FY | 25.54 Million CAD | 76.03% |
| 2023 Q2 | 14.65 Million CAD | 14.36% |
| 2022 Q4 | 14.51 Million CAD | 17.32% |
| 2022 Q3 | 12.37 Million CAD | -8.03% |
| 2022 FY | 14.51 Million CAD | 24.36% |
| 2022 Q2 | 13.45 Million CAD | 23.63% |
| 2022 Q1 | 10.87 Million CAD | -6.77% |
| 2021 Q1 | 7.84 Million CAD | -66.08% |
| 2021 FY | 11.66 Million CAD | -49.52% |
| 2021 Q3 | 12.07 Million CAD | 25.76% |
| 2021 Q4 | 11.66 Million CAD | -3.35% |
| 2021 Q2 | 9.6 Million CAD | 22.43% |
| 2020 Q4 | 23.11 Million CAD | 1.6% |
| 2020 Q3 | 22.75 Million CAD | 0.0% |
| 2020 FY | 23.11 Million CAD | 7.94% |
| 2019 FY | 21.41 Million CAD | 49.3% |
| 2019 Q4 | 21.41 Million CAD | 0.0% |
| 2018 FY | 14.34 Million CAD | 1849.47% |
| 2017 FY | 735.81 Thousand CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Appili Therapeutics Inc. | 12.41 Million CAD | -105.768% |
| Helix BioPharma Corp. | 1.57 Million CAD | -1517.887% |
| Microbix Biosystems Inc. | 11.02 Million CAD | -131.639% |
| Medicenna Therapeutics Corp. | 13.94 Million CAD | -83.22% |
| Satellos Bioscience Inc. | 3.62 Million CAD | -604.924% |
| Oncolytics Biotech Inc. | 11.25 Million CAD | -126.938% |
| Sernova Corp. | 9.59 Million CAD | -166.323% |